FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments have been game-changers for lung cancer and skin cancer, prostate cancer ...

The average age of men who get diagnosed is 67.

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

A new prostate cancer treatment could mean men suffer fewer side effects, scientists say. Trials will examine whether aquablation – a therapy using robotics, AI and real-time imaging – works as well ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

Consider this a PSA about PSA. Prostate cancer is the most common cancer in US men, excluding skin cancer, and the second-leading cause of male cancer deaths, after lung cancer. One in 6 men will be ...